Company / Financials
SANGAMO THERAPEUTICS, INC Financials
FY2011-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$39.6M
FY2025 · -31.6% YoY
Net Income
-$122.9M
FY2025 · -25.5% YoY
Profit Margin
-310.8%
FY2025 · net income / revenue
ROE
-
FY2025 · return on equity
Total Assets
$59.7M
FY2025
Total Debt
-
FY2025
Equity
-$14.3M
FY2025
ROA
-205.8%
FY2025 · return on assets
Statement paths
Financial highlights
Key Data Points
- Altman Z-Score -28.87 (distress zone, below 1.23 threshold)
- Piotroski F-Score: 2/9 criteria passed
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$39.6M-31.6% YoYNet Income HistoryProfit after all expenses and taxes-$122.9M-25.5% YoYOperating Income HistoryProfit from core business operations before interest and taxes-$121.2M-16.6% YoYSG&A Expense HistorySelling, general, and administrative expenses$34.9M-22.0% YoYR&D Expense HistoryResearch and development spending$112.7M+1.0% YoYIncome Tax HistoryTotal income tax expense-$568.0K-240.1% YoYEPS (Basic) HistoryBasic earnings per share-$0.49+66.9% YoYEPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$0.49+66.9% YoYShares Outstanding HistoryWeighted average diluted shares outstanding212.8M+19.5% YoYTotal Assets HistoryTotal value of all assets owned$59.7M-41.2% YoY